Statistics

Total Visits

Views
Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients46

Select a period of time:

Number of views in the range

Views
Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients37

Views

Views
January 20251
February 20255
March 202516
April 20253
May 20252
June 202510
July 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore16
Hong Kong10
United States6
Germany2
Spain1
Mexico1
Slovenia1
 

Top cities views

Views
Hong Kong10
Los Angeles2
Ameca1
Atlanta1
Council Bluffs1
Pasadena1